Timing of antiretroviral therapy initiation in a nationally representative sample of HIV-infected adults receiving medical care in the United States

AIDS Patient Care and STDs

Volumn 28, Issue 12, 2014, Pages 613-621

  Adedinsewo, Demilade A ^a,b   Wei, Stanley C ^b,c   Robertson, McKaylee ^a,b   Rose, Charles ^b   Johnson, Christopher H ^b   Dombrowski, Julie ^d,e   Skarbinski, Jacek ^b  

^a OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c U S PUBLIC HEALTH SERVICE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLACK PERSON; CAUCASIAN; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; DISEASE TRANSMISSION; FEMALE; HAZARD RATIO; HEALTH CARE DISPARITY; HEALTH INSURANCE; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEN WHO HAVE SEX WITH MEN; PROBABILITY SAMPLE; PROPORTIONAL HAZARDS MODEL; RACE DIFFERENCE; STANDARD; UNITED STATES; ADOLESCENT; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; HEALTH SURVEY; HIV INFECTIONS; INCIDENCE; INSURANCE; INTERVIEW; KAPLAN MEIER METHOD; MIDDLE AGED; PATIENT ATTITUDE; PROCEDURES; SEXUAL BEHAVIOR; STATISTICS AND NUMERICAL DATA; TIME; TIME TO TREATMENT; VIRUS LOAD; YOUNG ADULT;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; INSURANCE COVERAGE; INTERVIEWS AS TOPIC; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PROPORTIONAL HAZARDS MODELS; PUBLIC HEALTH SURVEILLANCE; SEXUAL BEHAVIOR; TIME FACTORS; TIME-TO-TREATMENT; UNITED STATES; VIRAL LOAD; YOUNG ADULT;

EID: 84918805004     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2014.0194     Document Type: Article

References (32)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguide lines/adultandadolescentgl.pdf (Last accessed July 29, 2014).
2. Walensky RP, Paltiel AD, Losina E, et al. Test and treat DC: Forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis 2010;51:392-400.
3. Early initiation of ART produces better clinical outcomes. Clin Infect Dis 2009;48:iii.
4. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
5. Geng EH, Hare CB, Kahn JO, et al. The effect of a "Universal Antiretroviral Therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/mul in a public health setting. Clin Infect Dis 2012;55:1690-1697.
6. Gianella S, von Wyl V, Fischer M, et al. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. An-tivir Ther 2011;16:535-545.
7. Crystal S, Sambamoorthi U, Moynihan PJ, McSpiritt E. Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS. J Gen Intern Med 2001;16:850-859.
8. Hsu LC, Truong HM, Vittinghoff E, Zhi Q, Scheer S, Schwarcz S. Trends in early initiation of antiretroviral therapy and characteristics of persons with HIV initiating therapy in San Francisco, 2007-2011. J Infect Dis 2014;209:1310-1314.
9. Mehta SH, Kirk GD, Astemborski J, Galai N, Celentano DD. Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore, Maryland, 1996-2008. Clin Infect Dis 2010;50:1664-1671.
10. Hanna DB, Buchacz K, Gebo KA, et al. Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis 2013;56:1174-1182.
11. DHHS. Protection of Human Subjects, US Federal Code Title 45 Part 46. Code of Federal Regulations, 2009.
12. CDC. Distinguishing Public Health Research and Public Health Nonresearch. In: Services HaH, ed, 2010.
13. Blair JM, McNaghten AD, Frazier EL, Skarbinski J, Huang P, Heffelfinger JD. Clinical and behavioral characteristics of adults receiving medical care for HIV infection-Medical Monitoring Project, United States, 2007. MMWR Surveill Summ 2011;60:1-20.
14. Frankel MR, McNaghten A, Shapiro MF, et al. A probability sample for monitoring the HIV-infected population in care in the U.S. and in selected states. Open AIDS J 2012;6:67-76.
15. McNaghten AD, Wolfe MI, Onorato I, et al. Improving the representativeness of behavioral and clinical surveillance for persons with HIV in the United States: The rationale for developing a population-based approach. PLoS One 2007;2:e550.
16. Blair JM, Fagan JL, Frazier EL, et al. Behavioral and clinical characteristics of persons receiving medical care for HIV infection-Medical Monitoring Project, United States, 2009. MMWR Surveill Summ 2014;63:1-22.
17. Kleinbaum DG, Klein M. Survival Analysis: Springer, 1996.
18. Kleinbaum DG, Klein M. Evaluating the proportional hazards assumption. Survival Analysis: Springer; 2012; pp. 161-200.
19. Kleinbaum DG. Epidemiologic methods: The "art" in the state of the art. J Clin Epidemiol 2002;55:1196-1200.
20. SAS: Survey Sampling and Analysis Procedures. https://support.sas.com/documentation/cdl/en/statug/63033/HTML/default/viewer.htm#statug-introsamp-sect001.htm (Last accessed June 6, 2014).
21. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study. JAMA 1999;281:2305-2315.
22. Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr 2000;25:115-123.
23. Hall HI, Byers RH, Ling Q, Espinoza L. Racial/ethnic and age disparities in HIV prevalence and disease progression among men who have sex with men in the United States. Am J Public Health 2007;97:1060-1066.
24. Hightow-Weidman LB, Smith JC, Valera E, Matthews DD, Lyons P. Keeping them in "STYLE": Finding, linking, and retaining young HIV-positive Black and Latino men who have sex with men in care. AIDS Patient Care STDS 2011;25:37-45.
25. Christopoulos KA, Das M, Colfax GN. Linkage and retention in HIV care among men who have sex with men in the United States. Clin Infect Dis 2011;52:S214-S222.
26. Beer L, Fagan JL, Garland P, et al. Medication-related barriers to entering HIV care. AIDS Patient Care STDS 2012;26:214-221.
27. Ghani AC, Donnelly CA, Anderson RM. Patterns of anti-retroviral use in the United States of America: Analysis of three observational databases. HIV Med 2003;4:24-32.
28. Hall HI, Frazier EL, Rhodes P, et al. Differences in human immunodeficiency virus care and treatment among sub-populations in the United States. JAMA Intern Med 2013;173:1337-1344.
29. Dombrowski JC, Kitahata MM, Van Rompaey SE, et al. High levels of antiretroviral use and viral suppression among persons in HIV care in the United States, 2010. J Acquir Immune Defic Syndr 2013;63:299-306.
30. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001;15:1707-1715.
31. Magidson JF, Seitz-Brown CJ, Listhaus A, Lindberg B, Anderson KE, Daughters SB. Distress tolerance and use of antiretroviral therapy among HIV-infected individuals in substance abuse treatment. AIDS Patient Care STDS 2013;27:518-523.
32. Gagliardo C, Murray M, Saiman L, Neu N. Initiation of an-tiretroviral therapy in youth with HIV: A U.S.-based provider survey. AIDS Patient Care STDS 2013;27:498-502.